Finland: Medtech startup AIATELLA has secured €2 million in funding to accelerate the development and scaling of its AI-powered cardiovascular imaging technology. The funding will help the company conduct clinical trials and develop its ultrasound-based preventative screening, which detects and quantifies carotid artery narrowing in minutes. The round was led by Helsinki-based Nordic Science Investments, with Specialist VC, Harjavalta Ventures, Business Finland, and a syndicate of angel investors also joining the round.

MindSpire, the neurotech start-up dedicated to helping people regulate stress and unlock peak performance, has raised £850,000 in pre-seed funding. This investment will support the launch of MindSpire's first device: SONA^TM, a medical-grade wearable that delivers precision-coded electrical pulses to the vagus nerve, activating brain circuits for calm, focus and enhanced learning.

The round was led by SFC Capital, with participation from SyndicateRoom and non-dilutive innovation funding secured via Innovate UK's Investor Partnership Programme. The £850,000 investment will enable MindSpire, based at the London Institute for Healthcare Engineering (LIHE), to complete the development and launch of SONA^TM.

Hampshire based startup, Zeus Sleep, has secured a £150,000 investment from British Design Fund to help accelerate the development of its groundbreaking solutions designed to alleviate the symptoms of snoring and sleep apnoea.

Bioniq, which is renowned for its personalized nutritional supplements based on blood biomarker data, has signed up football star Diogo Dalot, right-back for Manchester United and the Portugal national team, as an investor, contributing over €1 million.

Dalot joins the global football icon Cristiano Ronaldo, who became a major investor in 2024, and brought Bioniq's total valuation to $82 million. Dalot's investment marks another milestone in Bioniq's mission to make personalized health accessible to athletes and everyday individuals worldwide.

UK agritech startup Elaniti has closed its recent funding round with participation from early-stage biotech investor biotope by VIB, Planetary Impact Ventures and Paulig Group's CVC arm, PINC.

Healsgood, the pioneering healthtech company behind Flexzo AI, has successfully closed a £1.5 million funding round to revolutionise staffing and operational efficiency across the NHS. The oversubscribed round, led by Fuel Ventures, signifies strong investor confidence in Healsgood's vision of dramatically reducing patient waiting times and NHS service delivery failures across the UK.

Eventum Orthopaedics, a UK medtech company whose device could revolutionise knee replacement surgery has raised a further £3.8m from NPIF II - Mercia Equity Finance, which is managed by Mercia Ventures as part of the Northern Powerhouse Investment Fund II (NPIF II), Mercia’s EIS funds and private investors including leading surgeons.

Eventum's QuadSense device helps surgeons to precisely cut and place the kneecap in total knee replacements. Currently over 2 million patients a year have knee replacements globally, yet around 20% are not fully satisfied with the outcome. Eventum believes the key to improving success rates is the position of the kneecap, which plays a crucial role in the knee's function.

Reactwise has secured $3.4 million in pre-seed funding, including a competitive Innovate UK grant, to enable AI-driven robotic laboratories and speed up pharmaceutical manufacturing R&D. 

Edinburgh-based biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, a leading Scottish angel investment syndicate, bringing its total investment to £1 million in the last six months. This follows a £300,000 Innovate UK grant awarded recently, earlier, accelerating the development and commercialisation of its groundbreaking viral vector technology for next-generation cancer treatments.

Health and Care Innovations (HCI) has secured a £375,000 equity investment from the British Business Bank's South West Investment Fund via appointed Fund Manager, The FSE Group, as well as from new and existing angel investors.

StimOxyGen, a spin-out from Ulster University, has raised £1.5m, led by DSW Ventures, to accelerate the development of its innovative therapy designed to overcome treatment resistance in solid tumours.

Lant Medical has secured £500,000 investment from Innovate UK, the UK's innovation agency, and two angel investors from the Northern Investor Hub to design a clinical trial for a promising new non-antibiotic treatment, designed to eradicate cancer-causing Helicobacter pylori (H. pylori).